未登录.png)
分享.png)
收藏First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Autio, Karen A.; Higano, Celestia S.; Nordquist, Luke; Appleman, Leonard J.; Zhang, Tian; Zhu, Xin-Hua; Babiker, Hani; Vogelzang, Nicholas J.; Prasad, Sandip M.; Schweizer, Michael T.; Madan, Ravi A.; Billotte, Stephane; Cavazos, Nora; Bogg, Orlaith; Li, Ray; Chan, Kam; Cho, Helen; Kaneda, Megan; Wang, I-Ming; Zheng, Jenny; Tang, Szu-Yu; Hollingsworth, Robert; Kern, Kenneth A.; Petrylak, Daniel P. 分享 收藏 A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant gliomaReardon, David A.; Desjardins, Annick; Rixe, Olivier; Cloughesy, Timothy; Alekar, Shilpa; Williams, Jason H.; Li, Ray; Taylor, Carrie Turich; Lassman, Andrew B. 分享 收藏 RESULTS FROM A COMBINATION OF OX40 (PF-04518600) AND 4-1BB (UTOMILUMAB) AGONISTIC ANTIBODIES IN MELANOMA AND NON-SMALL CELL LUNG CANCER IN A PHASE 1 DOSE EXPANSION COHORTChiappori, Alberto; Thompson, John; Eskens, Fredericus; Spano, Jean-Philippe; Doi, Toshihiko; Hamid, Omid; Diab, Adi; Rizvi, Naiyer; Hu-Lieskovan, Siwen; Ros, Willeke; Thomas, Jacob; Forgie, Alison; Yang, Wenjing; Liao, Ken; Li, Ray; Kazazi, Farhad; Chou, Jeffrey; El Khoueiry, Anthony 分享 收藏 PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind studyPegram, Mark D.; Bondarenko, Igor; Costa Zorzetto, Marina Moreira; Hingmire, Sachin; Iwase, Hirotaka; Krivorotko, Petr V.; Lee, Keun Seok; Li, Rubi K.; Pikiel, Joanna; Aggarwal, Rajesh; Ewesuedo, Reginald; Freyman, Amy; Li, Ray; Vana, Alicia; Yin, Donghua; Zacharchuk, Charles; Tan-Chiu, Elizabeth 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
